NCT07940738
Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCy
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Recommended phase II dose (RP2D)
Timeframe: Up to 90 days
Absolute Lymphocyte Count Recovery
Timeframe: Up to 90 days
Secondary (1)
Occurrence of infections
Arms and interventions
Efineptakin Alfa (rhIL-7-hyFc)Experimental
Participants will receive a single intramuscular dose of efineptakin alfa (NT-I7, rhIL-7-hyFc) on Day +60 after allogeneic hematopoietic cell transplantation. Dose assignment will follow a phase 1 dose-escalation design with dose levels of 240 μg/kg, 480 μg/kg, and 720 μg/kg.
Drugs: Efineptakin Alfa (rhIL-7-hyFc)
Sites
1 site in 1 country
- Moffitt Cancer CenterTampa, Florida, United States